Total Revenue
Bristol-Myers Squibb Total Revenue decreased by 8.1% to $11.49B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.6%, from $11.20B to $11.49B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 1.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.70B | $11.62B | $11.99B | $11.65B | $11.89B | $11.22B | $11.41B | $11.34B | $11.23B | $10.97B | $11.48B | $11.87B | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B |
| QoQ Change | — | -0.7% | +3.1% | -2.8% | +2.1% | -5.6% | +1.7% | -0.6% | -1.0% | -2.3% | +4.7% | +3.4% | +2.8% | -2.5% | +3.8% | -9.2% | +9.5% | -0.4% | +2.3% | -8.1% |
| YoY Change | — | — | — | — | +1.6% | -3.5% | -4.8% | -2.7% | -5.6% | -2.2% | +0.6% | +4.7% | +8.7% | +8.4% | +7.5% | -5.6% | +0.6% | +2.8% | +1.3% | +2.6% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Eliquis | $3.42B | $3.00B | $3.20B | $3.57B | $3.68B | $3.75B | $3.45B | $4.14B |
| Opdivo | $2.39B | $2.36B | $2.48B | $2.27B | $2.56B | $2.53B | $2.69B | $2.15B |
| Orencia | $948.00M | $936.00M | $1.00B | $770.00M | $963.00M | $964.00M | $1.01B | $818.00M |
| Yervoy | $630.00M | $642.00M | $675.00M | $624.00M | $728.00M | $739.00M | $809.00M | $651.00M |
| Other Growth products | $341.00M | $433.00M | $512.00M | $403.00M | $470.00M | $514.00M | $537.00M | $581.00M |
| Reblozyl | $425.00M | $447.00M | $547.00M | $478.00M | $568.00M | $615.00M | $666.00M | $555.00M |
| Pomalyst/Imnovid | $959.00M | $898.00M | $823.00M | $658.00M | $708.00M | $675.00M | $692.00M | $513.00M |
| Breyanzi | $153.00M | $224.00M | $263.00M | $263.00M | $344.00M | $359.00M | $392.00M | $411.00M |
| Revlimid | $1.35B | $1.41B | $1.34B | $936.00M | $838.00M | $575.00M | $602.00M | $349.00M |
| Camzyos | $139.00M | $156.00M | $223.00M | $159.00M | $260.00M | $296.00M | $353.00M | $314.00M |
| Opdualag | $235.00M | $233.00M | $254.00M | $252.00M | $284.00M | $299.00M | $350.00M | $295.00M |
| Opdivo Qvantig | — | — | — | $9.00M | $30.00M | $67.00M | $132.00M | $163.00M |
| Other Legacy products | $222.00M | $225.00M | $250.00M | $199.00M | $223.00M | $177.00M | $199.00M | $156.00M |
| Zeposia | $151.00M | $147.00M | $158.00M | $107.00M | $150.00M | $161.00M | $159.00M | $118.00M |
| Sprycel | $424.00M | $290.00M | $198.00M | $175.00M | $120.00M | $119.00M | $79.00M | $73.00M |
| Sotyktu | $53.00M | $66.00M | $83.00M | $55.00M | $70.00M | $80.00M | $86.00M | $69.00M |
| Cobenfy | — | — | — | $27.00M | $35.00M | $43.00M | $50.00M | $56.00M |
| Abraxane | $231.00M | $253.00M | $174.00M | $105.00M | $105.00M | $74.00M | $84.00M | $50.00M |
| Krazati | $32.00M | $34.00M | $39.00M | $48.00M | $48.00M | $53.00M | $56.00M | $50.00M |
| Other revenue | — | — | — | — | — | — | — | -$15.00M |
| Abecma | $95.00M | $124.00M | $105.00M | $103.00M | $87.00M | $137.00M | $100.00M | — |
| Augtyro | $7.00M | $10.00M | $15.00M | — | — | — | — | — |
| Total | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B |
Abecma, Augtyro, Inrebic, Mature and other products, Mature Products And All Other, Onureg were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Geographic Breakdown
| Segment | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| International | — | — | — | — | — | $3.48B | $3.60B | $3.44B |
| Other | $185.00M | $199.00M | $176.00M | $271.00M | $218.00M | $270.00M | $290.00M | $257.00M |
| Total | $10.97B | $11.87B | $12.20B | $11.89B | $11.20B | $12.27B | $12.22B | $11.49B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's total revenue?
- Bristol-Myers Squibb (BMY) reported total revenue of $11.49B in Q1 2026.
- How has Bristol-Myers Squibb's total revenue changed year-over-year?
- Bristol-Myers Squibb's total revenue increased by 2.6% year-over-year, from $11.20B to $11.49B.
- What is the long-term trend for Bristol-Myers Squibb's total revenue?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's total revenue has grown at a 1.0% compound annual growth rate (CAGR), from $46.39B to $48.19B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.